anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a novel technology for extracting the effective component of the traditional Chinese medicine, particularly relates to a novel technical method of ultrasonic extraction, which high efficiently extracts the effective component of paeoniflorin from the compound traditional Chinese medicines of a honeysuckle, a red peony root and a male fern rhizome. The method adopts the design scheme of orthogonal experiment to obtain the dry honeysuckle, red peony root and male fern rhizome with the weight ratio of 3:3:1 by the filtration and ultrasonic extraction process based on the technical parameters of the ultrasonic intensity, the ultrasonic acting time and acting manner, the solvent type, the system temperature, the mixing manner etc., and the dry honeysuckle, red peony root and male fern rhizome are crushed and sieved (0.45 microns) as the material to be mixed with water, and the material-liquid volume ratio is 1:5 to 7. The ultrasonic power is 100W; the ultrasonic frequency is 25kHz; the ultrasonic acting manner is a separate excitation type ultrasonic vocalization device and a columnar radial-vibration transducer; the ultrasonic acting time is 40 minutes; the extraction temperature is 45 DEG C; the mixing manner is the gas lift-type mixing. The extracted liquid is filtered and condensed for the comparative consistency of 1.08 to 1.16, and ethanol is added till the alcohol content is 50 percent, and the liquid is mixed uniformly to be aged overnight and filtered; the filtrate is regenerated the ethanol and condensed; medical powder granules are obtained by spraying and drying at the extract flow velocity of 4 to 6 ml/min and the atomizing pressure of 1 to 2 kg. According to the method, the yield of the medical powder granular matter is 32 percent; the content of the paeoniflorin is 5.92 percent, which respectively improves by 32% and 30.9% compared with 25% of medical powder granular matter yield and 4.52% of the content of the paeoniflorin prepared by the traditional reflux method through pharmacopoeia (2005). The inventive method has characteristic of rapid, high efficient and economic compared with the traditional method.
Respiratory training will include training of the inspiratory and expiratory muscles seven times per week over eight weeks, during 40 minutes per day, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve device, regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
The present invention as described herein is aimed at combining a radiation-induced immunogenic effect with a T-cell therapy technique to markedly improve the therapeutic effectiveness of adoptive T-cell therapy with minimized toxicity. The method of this invention comprises, identifying a target tumor, applying ablative radiation treatment to the tumor in-situ, waiting for the production of CTLs primed by antigen presenting cells (APC), then resecting the target tumor from the patient. The CTLs are harvested and isolated from the tumor and undergo ex-vivo expansion and subsequent treatment of immune checkpoint blockades. The expanded CTLs are then infused back into the patient for systemic treatment of microscopic disease. The primed CTLs that are induced by radiation in-situ, are used as the source of T-cell therapy or other types of cell therapy. The harvested CTLs will have high tumor specificity with a wide range of heterogeneous tumor associated antigens (TAA) presentation.
Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
Premenstrual syndrome and premenstrual dysphoric disorder become episodically manifest during the second half of the female menstrual cycle and are characterized by psychological and physical symptoms causing relevant functional and social impairments. Mood swings, depression and dysphoria are associated depressive symptoms. Therefore, affective disorders should be considered as a differential diagnosis. Of women in reproductive age 3-8% suffer from premenstrual syndrome and 2% of women are affected by premenstrual dysphoric disorder. Genetic and sociobiographical risk factors are discussed. Furthermore, genetic polymorphisms of specific hormone receptors are considered to be genetic risk factors. From a pathophysiological perspective premenstrual syndrome and premenstrual dysphoric disorder are caused by a complex interaction between cyclic changes of ovarian steroids and central neurotransmitters. An imbalance of estrogen and progesterone in the luteal phase is believed to cause the symptoms. Therefore, the first treatment approach consists of regulation of the menstrual cycle or luteal support with progesterone or synthetic progestins even if their effectiveness has not yet been proven in randomized controlled studies and meta-analyses. The administration of combined oral contraceptives is also an option. Especially treatment with selective serotonin reuptake inhibitors (SSRI) represent an evidence-based approach. In severe cases the administration of gonadotropin releasing hormone (GnRH) agonists with add back treatment can also be considered. In the field of affective disorders premenstrual syndromes represent clinically relevant differential diagnoses and comorbidities, which confront the treating physician with particular clinical challenges. Therefore, this literature review gives the readership a clinical orientation for dealing with these disorders.
Parental communication about body weight with their children is common across diverse families. The current study investigates how parents' feelings about their own bodies, beliefs about body weight, history of weight stigma, and weight-related characteristics contribute to the degree to which they talk about weight - both negatively and positively - with their adolescent children. The study sample was comprised of U.S. parents (N = 1936) from diverse racial/ethnic backgrounds with children aged 10-17 years old. Parents completed an online survey with measures assessing their frequency of engaging in negative and positive weight communication with their children, along with several relevant psychosocial factors (i.e. body satisfaction, experienced weight stigma, associative stigma, body appreciation, beliefs about weight controllability, weight bias internalization). Study findings paint a complex picture, including some psychosocial factors (e.g. weight bias internalization) that are related to both more frequent negative and positive weight communication. Notably, higher levels of associative stigma were related to more frequent negative parental weight comments, and less frequent positive weight socialization. Findings can inform healthcare professionals in raising parents' awareness about how their personal beliefs and feelings about their own weight and their child's weight can contribute to how they engage in communication about weight with their children.
Post-isometric relaxation (PIR) was performed by a physiotherapist in a supine position. The physiotherapist sat on the head side of the patient. The painful side was determined, and the physiotherapist fixed the head with his/her hand and performed 50% voluntary isometric contraction of the painful muscle for 10 seconds. Then, the physiotherapist asked the patient to relax and stretch for 10 seconds to lateral flexion. This method was 10 repetitions with 10 seconds of rest between each repetition.
The efficacy of depo-subQ provera 104 in the reduction of endometriosis-associated pain in women with the signs and symptoms of endometriosis was demonstrated in two active comparator-controlled studies in pre-menopausal women 18 to 49 years of age with laparoscopically diagnosed endometriosis and persistent endometriosis pain symptoms (i.e., Studies 268 and 270). Each study assessed endometriosis-associated pain over 6 months of treatment and recurrence of symptoms for 12-months post treatment.

Subjects were treated for six months with depo-subQ provera 104 [104 mg given subcutaneously every 3 months (2 injections)] or leuprolide [11.25 mg given subcutaneously every 3 months (2 injections) or 3.75 mg given subcutaneously every month (6 injections)]. Study 268 was conducted in the U.S. and Canada and enrolled 274 subjects (136 subjects received depo-subQ provera 104 and 138 subjects received leuprolide). Study 270 was conducted in South America, Europe, and Asia, and enrolled 299 subjects (153 subjects received depo-subQ provera 104 and 146 subjects received leuprolide).

Reduction in endometriosis pain was evaluated using a modified Biberoglu and Behrman scale that consisted of three patient-reported symptoms (i.e., dysmenorrhea, dyspareunia, and pelvic pain not related to menses) and two signs assessed during pelvic examination (i.e., pelvic tenderness and induration). For each category, a favorable response was defined as improvement of at least 1 unit (severity was assessed on a scale of 0 to 3) relative to baseline score (Figure Q).

Additionally, scores from each of the five categories were combined into a composite score that was considered a global measurement of overall disease improvement. For subjects with baseline scores for each of the 5 categories, a mean decrease of 4 points relative to baseline was considered a clinically meaningful improvement. Across both studies, the mean changes in the composite score met the protocol-defined criterion for improvement for the depo-subQ provera 104 and leuprolide treatment groups.

In the clinical trials, treatment with depo-subQ provera 104 was limited to six months. Data on the persistence of benefit with longer treatment are not available.
The invention discloses a gynostemma pentaphyllum granule in sweet osmanthus flavor. The gynostemma pentaphyllum granule is prepared from following raw materials including, by weight, 100-120 parts of gynostemma pentaphyllum, 10-15 parts of black glutinous rice, 2-3 parts of milk-flavor powder, 8-10 parts of rice wine, 3-4 parts of tilia europaea, 1-2 parts of semen celosiae, 2-3 parts of schisandra chinensis, 4-5 parts of fructus mume, 3-4 parts of rhodiola rosea, 1-2 parts of polyalthia nemoralis, a proper amount of a flower-made coating and a proper amount of pomegranate seed oil. In the invention, fresh gynostemma pentaphyllum is directly freeze-dried and ultrafine-grinded so that nutritional components of the gynostemma pentaphyllum are maximumly protected. The gynostemma pentaphyllum is prepared into small medicinal granules so that the gynostemma pentaphyllum can be directly taken orally without being decocted in water. A preparation method is simple and quick, is suitable for industrialized production and is wide in market prospect. Through addition of sweet osmanthus and stachyose, a bitter and astringent taste of the medicinal granules is covered so that the gynostemma pentaphyllum is better in mouthfeel and is easy to take. Through addition of the rice wine, the medicinal granules have a thick wine fragrance. Through addition of the traditional Chinese medicine raw materials, the medicinal granules have a significant nutritional and health-caring effect.
Histopathology is the gold standard for diagnosing fibrosis, but its routine use is constrained by the need for additional stains, time, personnel and resources. Vibrational spectroscopy is a novel technique that offers an alternative atraumatic approach, with short scan times, while providing metabolic and morphological data. This review evaluates vibrational spectroscopy for the assessment of fibrosis, with a focus on point-of-care capabilities. OVID Medline, Embase and Cochrane databases were systematically searched using PRISMA guidelines for search terms including vibrational spectroscopy, human tissue and fibrosis. Studies were stratified based on imaging modality and tissue type. Outcomes recorded included tissue type, machine learning technique, metrics for accuracy and author conclusions. Systematic review yielded 420 articles, of which 14 were relevant. Ten of these articles considered mid-infrared spectroscopy, three dealt with Raman spectroscopy and one with near-infrared spectroscopy. The metrics for detecting fibrosis were Pearson correlation coefficients ranging from 0.65-0.98; sensitivity from 76-100%; specificity from 90-99%; area under receiver operator curves from 0.83-0.98; and accuracy of 86-99%. Vibrational spectroscopy identified fibrosis in myeloproliferative neoplasms in bone, cirrhotic and hepatocellular carcinoma in liver, end-stage heart failure in cardiac tissue and following laser ablation for acne in skin. It also identified interstitial fibrosis as a predictor of early renal transplant rejection in renal tissue. Vibrational spectroscopic techniques can therefore accurately identify fibrosis in a range of human tissues. Emerging data show that it can be used to quantify, classify and provide data about the nature of fibrosis with a high degree of accuracy with potential scope for point-of-care use.
PURPOSE:To obtain a new compound having strong collagenase inhibiting action and useful for treatment of arthritis, periodontitis, corneal ulcer, etc. CONSTITUTION:A compound of formula I (R<1> is H, methoxy or OH), e.g. 4(S)-[3- hydroxyaminocarbonyl-2(R)-(2-methylpropyl)-propanoyl] aminol,2,4,5-tetrahydro-3 H-2-benzazepin-3-one. This compound of formula I is obtained by subjecting a compound of formula II (Bzl is benzyl) to hydrocracking or by condensing a compound of formula III with hydroxylamine. The hydrocracking is carried out by subjecting the compound of formula III to catalytic reduction in a lower alcohol such as methanol in the presence of Pd catalyst in a stream of hydrogen or under hydrogen pressure at ambient temperature to 60 deg.C. The condensation reaction is carried out by using a condensing agent (e.g. dicyclohexylcarbodiimide) or by means of a method using a mixed acid anhydrides.
INTRODUCTION: Cardiac complications after major noncardiac surgery are common and associated with high morbidity and mortality. How preoperative use of beta-blockers may impact perioperative cardiac complications remains unclear.
METHODS: In a multicentre prospective cohort study, preoperative beta-blocker use was ascertained in consecutive patients at elevated cardiovascular risk undergoing major noncardiac surgery. Cardiac complications were prospectively monitored and centrally adjudicated by two independent experts. The primary endpoint was perioperative myocardial infarction or injury attributable to a cardiac cause (cardiac PMI) within the first three postoperative days. The secondary endpoints were major adverse cardiac events (MACE), defined as a composite of myocardial infarction, acute heart failure, life-threatening arrhythmia, and cardiovascular death and all-cause death after 365 days. We used inverse probability of treatment weighting to account for differences between patients receiving beta-blockers and those who did not.
RESULTS: A total of 3839/10 272 (37.4%) patients (mean age 74 yr; 44.8% female) received beta-blockers before surgery. Patients on beta-blockers were older, and more likely to be male with established cardiorespiratory and chronic kidney disease. Cardiac PMI occurred in 1077 patients, with a weighted odds ratio of 1.03 (95% confidence interval [CI] 0.94-1.12, P=0.55) for patients on beta-blockers. Within 365 days of surgery, 971/10 272 (9.5%) MACE had occurred, with a weighted hazard ratio of 0.99 (95% CI 0.83-1.18, P=0.90) for patients on beta-blockers.
CONCLUSION: Preoperative use of beta-blockers was not associated with decreased cardiac complications including cardiac perioperative myocardial infarction or injury and major adverse cardiac event. Additionally, preoperative use of beta-blockers was not associated with increased all-cause death within 30 and 365 days.
CLINICAL TRIAL REGISTRATION: NCT02573532.
BACKGROUND: Work-related musculoskeletal disorders are widespread among workers of informal small-scale enterprises. Specifically, lower back pain is a prevalent occupational health problem across various industries, including weaving factories. Lower back pain significantly impairs the functioning, performance, and productivity of weavers. However, information on the prevalence and associated factors of low back pain among weavers of Bahir Dar City and nationwide is scarce. Therefore, this study aimed to assess the prevalence and associated factors of lower back pain among weavers working in Bahir Dar City.
METHOD: A multicentered institutional-based cross-sectional study was conducted on 403 weavers in Bahir Dar City, Ethiopia, from April to May 2023 using a structured face-to-face interview questionnaire. Samples were proportionally allocated to each institution, and study participants were selected using a simple random sampling technique. Variables with a P-value < 0.25 in the bivariate logistic regression were adopted for the multivariate logistic regression analysis after verifying the model fitness. In the multivariate logistic regression analysis, the adjusted odds ratio (AOR) with a 95% confidence interval (CI) and a P-value < 0.05 were considered to identify the associated factors of lower back pain among weavers.
RESULT: The results revealed that the overall annual prevalence of lower back pain was 63.5% (95% CI = 58.8-68.5). Longer working hours [AOR = 2.580 (CI = 1.517-4.384)], lack of back support [AOR = 1.938 (CI = 2.089-3.449)], repetitive movement of the back during weaving [AOR = 5.940 (CI = 2.709-13.02)], awkward posture [AOR = 2.915 (CI = 1.677-5.065), static working posture [AOR = 4.505 (CI = 2.298-8.831)], and job stress [AOR = 3.306 (CI = 1.896-5.765)] were significantly associated with lower back pain among weavers.
CONCLUSIONS: Lower back pain among weavers was found to be highly prevalent. Working longer hours, lack of back support, repetitive movement of the back, awkward posture, static posture, and job stress were significantly associated with lower back among weavers. The study recommends prompt interventions on weavers to ensure that they use sitting support, weave for <8 h per day, change positions every 2 h, reduce job-related stress, and minimize task repetition, thereby enhancing their working conditions and minimizing the occurrence of lower back pain.
The literature concludes that patients should be allowed food without delay (at will) after colorectal surgery and that the customary withholding of oral intake (nil-by-mouth) for the first postoperative days is unnecessary. Robust data also suggest that the investigators should avoid the nil-by-mouth regimen after major gynecologic, urologic, and vascular surgery. The safety of early oral feeding after esophagectomy has not been investigated previously.In 2008, the results of a randomized multicenter clinical trial investigating whether a routine of allowing normal food at will immediately increases morbidity after major upper gastrointestinal surgery showed that allowing patients to eat normal food at will from the first day after major upper gastrointestinal surgery does not increase morbidity compared with traditional care with nil-by-mouth and enteral feeding. The assumed hazards of allowing oral food intake in the immediate postoperative period in patients with esophagectomy have not been scientifically tested and should be viewed against both the benefits and side effects of any artificial feeding modality.

This is a randomized study investigating the role of early oral feeding in patients with esophagectomy.In the early oral feeding group nasogastric tube is not placed routinely and patients are encouraged to intake liquid food on postoperative day 1 (POD1). In delayed oral feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20 mL/h until the morning of POD 1. Nutrition was then commenced at 20 mL/h. The rate was increased by 20 mL/h each day if tolerated, up to 80 mL/h. Esophagography is performed on postoperative day 7. Sip of water were allowed after confirming the absence of anastomotic leakage, and a full liquid diet was implemented on the following day and enteral infusion halted. The complications defined in previous study and bowel function and recovery were recorded carefully. The primary end point of this study is the postoperative complications and the secondary end points are quality of life,bowel function recovery time and length of postoperative stay between the two groups. The investigators estimated the minimum rate of patients with complications in control group population at 23%. An increase of this to 36% was considered clinically important. Detecting a difference of this magnitude or greater at a level of statistical significance of 0.05 and a power of 0.90 with a one-tailed test of proportions required a total of 130 patients in each group.Considering the rate of drop-out a total of 280 patients will be enrolled in this study.
PURPOSE: To present the initial prospective clinical assessment of the ILY® robotic ureteroscopy manipulator platform, focusing on its safety and effectiveness.
METHODS AND MATERIALS: Data gathered from 31 kidney units which underwent elective robotic flexible ureteroscopy (FURS) for renal stone management utilizing the ILY® robotic system. Patient demographics, stone characteristics, surgical durations, perioperative and post-operative complications, and follow-up parameters were collected. Our primary outcome was evaluating the efficacy and safety of the ILY® robotic ureteroscopy for treating kidney stones. Therefore, we analyzed complication rates, surgical durations, and the stone-free rate during follow-up.
RESULTS: Our cohort consisted of 29 patients, presenting with 45 stones with a median volume of 736.22 mm3. The median operation time was 85 min, accompanied by 3 min for robot draping, 3.5 min for robot docking, 48 min of console operation, and lasing time of 36.75 min. Post operative stay for all patients was 1 day, while complications were observed in 9.68% of cases. Notably, all complications were classified as CVD (Clavien-Dindo) class 1 due to pain requiring emergency department visit. The stone-free rate achieved was 93.55%, and none of the patient required reoperation for the treated stone.
CONCLUSION: In the first prospective clinical experience of the ILY® robotic FURS, we demonstrated its efficacy and safety. To further investigate its clinical practical value, additional investigations are warranted, including direct comparative analyses with manual flexible ureteroscopy techniques.
This patent concerns the discovery of the effectiveness of an alcoholic total extract of the aerial parts of the plant Anisotes trisulcus (Forssk.) Vahl family Acanthaceae and its active constituent peganine as a new means for suppression of tobacco intake and as a suppression to appetite (as anororexiants). The treatment of Wistar rats with the total alcoholic extract in doses of 600 mg/100 ml drinking water decreased oral nicotine intake by 87.7% and food intake by 84.9%. The active constituent peganine in doses of 1.4 mg/ml drinking water decreased nicotine consumption by 79% and food intake by 77.8%. In other experimental in mice, the extract enhanced nicotine actions by more than 70% and mimicked nicotine in inducing intestinal stimulation in the isolated guinea pig ileum. Peganine is hereby claimed to be a new deterrent for tobacco intake.